Aurinia Pharmaceuticals P/E Ratio

Aurinia Pharmaceuticals (AUPH) currently reports a P/E ratio of 6.64. That is below the Healthcare sector average of 27.42. Use the charts on this page to explore Aurinia Pharmaceuticals's P/E ratio history and peer comparisons.

Aurinia Pharmaceuticals's P/E ratio of 6.64 is lower than the Healthcare sector average of 27.42. That is roughly 75.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Aurinia Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 6.64, AUPH can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 6.64, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.42. From there, open related valuation or income-statement pages for Aurinia Pharmaceuticals, and consider following AUPH for alerts when major investors trade the stock.

Aurinia Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows 6.64 versus a sector average near 27.42. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AUPH with unrelated industries.